Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
Overview
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
Source
Originally published at www.marketwatch.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.